Do analysts prefer SXTPW or NTHI?

Neonc Technologies has a consensus price target of $16.00, indicating a potential upside of 279.15%. Given Neonc Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Neonc Technologies is more favorable than 60 Degrees Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 60 Degrees Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Neonc Technologies 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has stronger valuation and earnings, SXTPW or NTHI?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 60 Degrees Pharmaceuticals $1.00M N/A N/A N/A N/A Neonc Technologies $39.99K N/A N/A N/A N/A

Is SXTPW or NTHI more profitable?

Company Net Margins Return on Equity Return on Assets 60 Degrees Pharmaceuticals N/A N/A N/A Neonc Technologies N/A N/A N/A

Does the media refer more to SXTPW or NTHI?

In the previous week, Neonc Technologies had 14 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 16 mentions for Neonc Technologies and 2 mentions for 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals' average media sentiment score of 1.87 beat Neonc Technologies' score of -0.09 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 60 Degrees Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Neonc Technologies 1 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend NTHI or BFRIW?

Neonc Technologies presently has a consensus price target of $16.00, indicating a potential upside of 279.15%. Given Neonc Technologies' stronger consensus rating and higher possible upside, equities research analysts clearly believe Neonc Technologies is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neonc Technologies 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Biofrontera 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, NTHI or BFRIW?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neonc Technologies $39.99K N/A N/A N/A N/A Biofrontera $43.20M N/A N/A N/A N/A

Is NTHI or BFRIW more profitable?

Company Net Margins Return on Equity Return on Assets Neonc Technologies N/A N/A N/A Biofrontera N/A N/A N/A

Does the media prefer NTHI or BFRIW?

In the previous week, Neonc Technologies had 13 more articles in the media than Biofrontera. MarketBeat recorded 16 mentions for Neonc Technologies and 3 mentions for Biofrontera. Biofrontera's average media sentiment score of 0.96 beat Neonc Technologies' score of -0.09 indicating that Biofrontera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neonc Technologies 1 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Biofrontera 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate CALA or NTHI?

Neonc Technologies has a consensus target price of $16.00, indicating a potential upside of 279.15%. Given Neonc Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Neonc Technologies is more favorable than Calithera Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calithera Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Neonc Technologies 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has better earnings and valuation, CALA or NTHI?

Neonc Technologies has higher revenue and earnings than Calithera Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Calithera Biosciences N/A N/A -$39.65M N/A N/A Neonc Technologies $39.99K N/A N/A N/A N/A

Is CALA or NTHI more profitable?

Company Net Margins Return on Equity Return on Assets Calithera Biosciences N/A N/A N/A Neonc Technologies N/A N/A N/A

Do analysts recommend CINGW or NTHI?

Neonc Technologies has a consensus target price of $16.00, suggesting a potential upside of 279.15%. Given Neonc Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Neonc Technologies is more favorable than Cingulate. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cingulate 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Neonc Technologies 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has preferable earnings and valuation, CINGW or NTHI?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cingulate N/A N/A N/A N/A N/A Neonc Technologies $39.99K N/A N/A N/A N/A

Is CINGW or NTHI more profitable?

Company Net Margins Return on Equity Return on Assets Cingulate N/A N/A N/A Neonc Technologies N/A N/A N/A

Do analysts rate CMRAW or NTHI?

Neonc Technologies has a consensus price target of $16.00, suggesting a potential upside of 279.15%. Given Neonc Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Neonc Technologies is more favorable than Comera Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Comera Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Neonc Technologies 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has preferable earnings & valuation, CMRAW or NTHI?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Comera Life Sciences $1.00M N/A N/A N/A N/A Neonc Technologies $39.99K N/A N/A N/A N/A

Is CMRAW or NTHI more profitable?

Company Net Margins Return on Equity Return on Assets Comera Life Sciences N/A N/A N/A Neonc Technologies N/A N/A N/A

Neonc Technologies (NTHI) Competitors

$4.22 +1.01 (+31.46%)

Closing price 04:00 PM Eastern

Extended Trading

$4.18 -0.04 (-0.83%)

As of 07:42 PM Eastern

Compare

NTHI vs. SXTPW, BFRIW, CALA, CINGW, and CMRAW

Should you buy Neonc Technologies stock or one of its competitors? Neonc Technologies's main competitors and comparable companies include 60 Degrees Pharmaceuticals (SXTPW), Biofrontera (BFRIW), Calithera Biosciences (CALA), Cingulate (CINGW), and Comera Life Sciences (CMRAW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Neonc Technologies compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTPW) and Neonc Technologies (NASDAQ:NTHI) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$1.00M	N/A	N/A	N/A	N/A
Neonc Technologies	$39.99K	N/A	N/A	N/A	N/A

In the previous week, Neonc Technologies had 14 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 16 mentions for Neonc Technologies and 2 mentions for 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals' average media sentiment score of 1.87 beat Neonc Technologies' score of -0.09 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
60 Degrees Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Neonc Technologies	1 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Neonc Technologies has a consensus price target of $16.00, indicating a potential upside of 279.15%. Given Neonc Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Neonc Technologies is more favorable than 60 Degrees Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Neonc Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Company	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	N/A	N/A	N/A
Neonc Technologies	N/A	N/A	N/A

Summary

Neonc Technologies beats 60 Degrees Pharmaceuticals on 4 of the 6 factors compared between the two stocks.

How does Neonc Technologies compare to Biofrontera?

Neonc Technologies (NASDAQ:NTHI) and Biofrontera (NASDAQ:BFRIW) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neonc Technologies	$39.99K	N/A	N/A	N/A	N/A
Biofrontera	$43.20M	N/A	N/A	N/A	N/A

In the previous week, Neonc Technologies had 13 more articles in the media than Biofrontera. MarketBeat recorded 16 mentions for Neonc Technologies and 3 mentions for Biofrontera. Biofrontera's average media sentiment score of 0.96 beat Neonc Technologies' score of -0.09 indicating that Biofrontera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neonc Technologies	1 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Biofrontera	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neonc Technologies presently has a consensus price target of $16.00, indicating a potential upside of 279.15%. Given Neonc Technologies' stronger consensus rating and higher possible upside, equities research analysts clearly believe Neonc Technologies is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neonc Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Biofrontera	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Neonc Technologies	N/A	N/A	N/A
Biofrontera	N/A	N/A	N/A

Summary

Neonc Technologies beats Biofrontera on 4 of the 6 factors compared between the two stocks.

How does Neonc Technologies compare to Calithera Biosciences?

Calithera Biosciences (NASDAQ:CALA) and Neonc Technologies (NASDAQ:NTHI) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Company	Net Margins	Return on Equity	Return on Assets
Calithera Biosciences	N/A	N/A	N/A
Neonc Technologies	N/A	N/A	N/A

Neonc Technologies has higher revenue and earnings than Calithera Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calithera Biosciences	N/A	N/A	-$39.65M	N/A	N/A
Neonc Technologies	$39.99K	N/A	N/A	N/A	N/A

Neonc Technologies has a consensus target price of $16.00, indicating a potential upside of 279.15%. Given Neonc Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Neonc Technologies is more favorable than Calithera Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calithera Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Neonc Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Neonc Technologies had 16 more articles in the media than Calithera Biosciences. MarketBeat recorded 16 mentions for Neonc Technologies and 0 mentions for Calithera Biosciences. Calithera Biosciences' average media sentiment score of 0.00 beat Neonc Technologies' score of -0.09 indicating that Calithera Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Calithera Biosciences	Neutral
Neonc Technologies	Neutral

Summary

Neonc Technologies beats Calithera Biosciences on 5 of the 6 factors compared between the two stocks.

How does Neonc Technologies compare to Cingulate?

Cingulate (NASDAQ:CINGW) and Neonc Technologies (NASDAQ:NTHI) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Neonc Technologies has a consensus target price of $16.00, suggesting a potential upside of 279.15%. Given Neonc Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Neonc Technologies is more favorable than Cingulate.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Neonc Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	N/A	N/A
Neonc Technologies	N/A	N/A	N/A

In the previous week, Neonc Technologies had 14 more articles in the media than Cingulate. MarketBeat recorded 16 mentions for Neonc Technologies and 2 mentions for Cingulate. Cingulate's average media sentiment score of 1.44 beat Neonc Technologies' score of -0.09 indicating that Cingulate is being referred to more favorably in the media.

Company	Overall Sentiment
Cingulate	Positive
Neonc Technologies	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	N/A	N/A	N/A
Neonc Technologies	$39.99K	N/A	N/A	N/A	N/A

Summary

Neonc Technologies beats Cingulate on 5 of the 6 factors compared between the two stocks.

How does Neonc Technologies compare to Comera Life Sciences?

Comera Life Sciences (NASDAQ:CMRAW) and Neonc Technologies (NASDAQ:NTHI) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Comera Life Sciences	$1.00M	N/A	N/A	N/A	N/A
Neonc Technologies	$39.99K	N/A	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Comera Life Sciences	N/A	N/A	N/A
Neonc Technologies	N/A	N/A	N/A

Neonc Technologies has a consensus price target of $16.00, suggesting a potential upside of 279.15%. Given Neonc Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Neonc Technologies is more favorable than Comera Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Comera Life Sciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Neonc Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Neonc Technologies had 16 more articles in the media than Comera Life Sciences. MarketBeat recorded 16 mentions for Neonc Technologies and 0 mentions for Comera Life Sciences. Comera Life Sciences' average media sentiment score of 0.00 beat Neonc Technologies' score of -0.09 indicating that Comera Life Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Comera Life Sciences	Neutral
Neonc Technologies	Neutral

Summary

Neonc Technologies beats Comera Life Sciences on 4 of the 6 factors compared between the two stocks.

Get Neonc Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NTHI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NTHI vs. The Competition

Export

Metric	Neonc Technologies	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	N/A	$11.89B	$7.06B	$13.10B
Dividend Yield	N/A	2.70%	2.57%	10.45%
P/E Ratio	N/A	640.15	211.09	21.74
Price / Sales	N/A	743.87	602.98	92.99
Price / Cash	N/A	66.45	70.48	50.90
Price / Book	N/A	11.60	12.91	6.24
Net Income	N/A	$2.77B	$3.45B	$347.60M
7 Day Performance	20.57%	0.17%	1.12%	1.07%
1 Month Performance	14.67%	0.35%	1.79%	1.03%
1 Year Performance	-18.69%	161.52%	67.69%	20.77%

Neonc Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NTHI Neonc Technologies	N/A	$4.22 +31.5%	$16.00 +279.1%	-39.7%	$0.00	$39.99K	N/A	8	News Coverage Earnings Report High Trading Volume
SXTPW 60 Degrees Pharmaceuticals	N/A	$0.03 flat	N/A	-67.6%	$0.00	$1.00M	N/A	2	News Coverage Positive News Gap Up
BFRIW Biofrontera	N/A	$0.03 +0.4%	N/A	-81.6%	$0.00	$43.20M	N/A	70	News Coverage Short Interest Decrease
CALA Calithera Biosciences	N/A	N/A	N/A	N/A	$0.00	N/A	N/A	60	Upcoming Earnings
CINGW Cingulate	N/A	$0.01 -2.2%	N/A	-87.9%	$0.00	N/A	N/A	20	Positive News Upcoming Earnings Short Interest Decrease Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NTHI) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neonc Technologies (NTHI) Competitors

NTHI vs. SXTPW, BFRIW, CALA, CINGW, and CMRAW

How does Neonc Technologies compare to 60 Degrees Pharmaceuticals?

Summary

How does Neonc Technologies compare to Biofrontera?

Summary

How does Neonc Technologies compare to Calithera Biosciences?

Summary

How does Neonc Technologies compare to Cingulate?

Summary

How does Neonc Technologies compare to Comera Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTHI vs. The Competition

Neonc Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neonc Technologies (NTHI) Competitors

NTHI vs. SXTPW, BFRIW, CALA, CINGW, and CMRAW

How does Neonc Technologies compare to 60 Degrees Pharmaceuticals?

Which has stronger valuation and earnings, SXTPW or NTHI?

Does the media refer more to SXTPW or NTHI?

Do analysts prefer SXTPW or NTHI?

Is SXTPW or NTHI more profitable?

Summary

How does Neonc Technologies compare to Biofrontera?

Which has stronger valuation and earnings, NTHI or BFRIW?

Does the media prefer NTHI or BFRIW?

Do analysts recommend NTHI or BFRIW?

Is NTHI or BFRIW more profitable?

Summary

How does Neonc Technologies compare to Calithera Biosciences?

Is CALA or NTHI more profitable?

Which has better earnings and valuation, CALA or NTHI?

Do analysts rate CALA or NTHI?

Does the media favor CALA or NTHI?

Summary

How does Neonc Technologies compare to Cingulate?

Do analysts recommend CINGW or NTHI?

Is CINGW or NTHI more profitable?

Does the media refer more to CINGW or NTHI?

Which has preferable earnings and valuation, CINGW or NTHI?

Summary

How does Neonc Technologies compare to Comera Life Sciences?

Which has preferable earnings & valuation, CMRAW or NTHI?

Is CMRAW or NTHI more profitable?

Do analysts rate CMRAW or NTHI?

Does the media favor CMRAW or NTHI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTHI vs. The Competition

Neonc Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools